OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer|HER2 Negative Breast Carcinoma
Interventions: DRUG: OP-1250|DRUG: Fulvestrant|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane
Sponsor: Olema Pharmaceuticals, Inc.